

Ticket #: _____ Request Date: _____ Request Time: _____

Bravelle® Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
<input type="checkbox"/> Check if requesting brand	Directions for Use:	
<input type="checkbox"/> Check if request is for continuation of therapy		

Clinical Information (required)	
Select the diagnosis below:	
<input type="checkbox"/> Controlled ovarian hyperstimulation	
<input type="checkbox"/> Male hypogonadotropic hypogonadism	
<input type="checkbox"/> Ovulation induction	
<input type="checkbox"/> Other diagnosis: _____	ICD-10 Code(s): _____

For all diagnoses, answer the following:

Is this medication prescribed by or in consultation with a reproductive endocrinologist? Yes No

Does the patient have history of trial, failure, or contraindication to Gonal-f/Gonal-f RFF (follitropin alfa)? Yes No

For controlled ovarian hyperstimulation, answer the following:

Does the patient have a diagnosis of infertility? Yes No

Is this medication being used for the development of multiple follicles (controlled ovarian hyperstimulation)? Yes No

Is the medication for an ovulatory female patient participating in an assisted reproductive technology (ART) program? Yes No

For male hypogonadotropic hypogonadism, answer the following:

Select the diagnosis:

Male primary hypogonadotropic hypogonadism

Male secondary hypogonadotropic hypogonadism

Is this medication being used for induction of spermatogenesis? Yes No

Is the infertility due to primary testicular failure? Yes No

For ovulation induction, answer the following:

Does the patient have a diagnosis of anovulatory infertility? Yes No

Is the infertility due to primary ovarian failure? Yes No

Is this medication being used for the induction of ovulation? Yes No

Please note that this form is to be completed by the prescribing physician. This document and others, if attached, contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. This form and its contents are permissible under HIPAA as the protected health information (PHI) contained in this letter is only being used for purposes related to the provision of treatment, payment and healthcare operations (TPO). Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately.

Office use only: Bravelle_Comm_2017Dec

Bravelle® Prior Authorization Request Form (Page 2 of 2)
DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Authorized Medical Signature:

Telephone:

Date:

When Completed Return To:

ProCare PBM Clinical Division, 1267 Professional Parkway, Gainesville, GA 30507
1-866-965-Drug (3784) / Fax # 866-999-7736

Please note: This request may be denied unless all required information is received.

Please note that this form is to be completed by the prescribing physician. This document and others, if attached, contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. This form and its contents are permissible under HIPAA as the protected health information (PHI) contained in this letter is only being used for purposes related to the provision of treatment, payment and healthcare operations (TPO). Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately.

Office use only: Bravelle_Comm_2017Dec